- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
TheraKine and Capsulution Start Joint Development
Capsulution NanoScience AG, a Berlin-based company, and TheraKine Ltd., an Irish company with significant operations in the United States, are establishing a joint project for the treatment of serious eye diseases. Their aim is to develop an innovative drug-delivery system for ophthalmic applications which will enable local sustained release of one or multiple anti-inflammatory and anti-proliferative biologic and small molecule compounds. This will allow the therapy of difficult to treat eye diseases such as uveitis, diabetic retinopathy and age-related macular degeneration (AMD).
The current treatment possibilities for inflammation of the eye are more than unsatisfactory. Steroids and immunosuppressants have many severe side effects and limited efficacy. Biologic compounds need regularly repeated intravenously or intravitreal injections at relatively high doses. When administered systemically, only traces of the compound reach the interior of the eye, but cause undesirable side effects due to high levels of the compound in other parts of the body. Intravitreal injections offer a solution to this; but currently these still require repeated injections and are limited to a small number of anti-VEGF drugs or long acting steroids. Only a small fraction of patients can be treated with current technology, and there are significant side effects such as internal bleeding, cataracts, retinal damage, increase of pressure inside the eye, and infection.
With the aid of Capsulution's formulation technology, TheraKine will bring an innovative drug-delivery system to the market. "We selected Capsulution because they have the right IP, skilled staff, and an entrepreneurial spirit.", explains TheraKine's CEO Scott Hampton. The collaboration with the internationally-renowned developer of nanocomplexes offers a promising advance towards the formulation of very easily degradable, water-soluble biologic compounds in combination with water-insoluble anti-inflammatory compounds or small molecules. According to Capsulution's Project CSO, Dr. Voigt: "For this application, controlled and sustained release of a pre-defined amount of compound is required." The compound depot in the biodegradable implant should, if possible, only be injected into the eye once.
Mr. Hampton declares: "TheraKine's mission is the creation of therapeutic system to improve vision and prevent blindness". He emphasizes the urgency of the situation: "Effective and safe treatments are desperately needed by millions of people who are currently suffering progressive vision loss due to chronic inflammatory and degenerative eye diseases. Our targeted local delivery will offer safety, effectiveness, and affordable treatment costs."
About Capsulution NanoScience AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.
TheraKine was founded in 2004 when a widely respected physician
discovered better treatments for children who were rapidly losing
their eyesight due to chronic inflammatory eye disease. Frustrated by
the limitations of existing systemic delivery systems, the TheraKine
team soon decided that a local, targeted approach to delivery would
produce a much more effective and efficient outcome for the patient.
This work continues, with exciting results in feasibility trials.
TheraKine estimates that the first human clinical trials will start
in the fourth quarter of 2009.
For more information, please click here
Herr Dipl.-Kfm. Alexander Herrmann
Telefon: +49 (30) 6706919-129
Fax: +49 (30) 6706919-101
Zuständigkeitsbereich: Chief Financial Officer (CFO)
Herr Jerry Seelig
Telefon: +1 (678) 648-4037
Fax: +1 (678) 623-9550
Zuständigkeitsbereich: Senior Business Development
Copyright © Capsulution NanoScience AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nuclear pores captured on film: Using an ultra fast-scanning atomic force microscope, researchers from the University of Basel have filmed 'living' nuclear pore complexes at work for the first time May 3rd, 2016
FEI Launches Apreo – Industry-Leading Versatile, High-Performance SEM: The Apreo SEM provides high-resolution surface information with excellent contrast, and the flexibility to accommodate a large range of samples, applications and conditions May 4th, 2016
Electrically Conductive Graphene Ink Enables Printing of Biosensors April 23rd, 2016
Leti Extends Collaboration with Qualcomm on CoolCubeTM 3D Integration Technology for High-Density, High-Performance ICs: Collaboration Goals Include Building an Ecosystem To Take the Chip-stacking Technology from Design to Fabrication April 13th, 2016
Cooling graphene-based film close to pilot-scale production April 30th, 2016
Personal cooling units on the horizon April 29th, 2016
Exploring phosphorene, a promising new material April 29th, 2016